UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.263

Sortiert nach

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus

The New England journal of medicine, 2010-04, Vol.362 (17), p.1563-1574

2010

Link zum Volltext

Verfügbarkeit prüfen

Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration

Molecular pharmaceutics, 2019-05, Vol.16 (5), p.1958-1970

2019

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of a New Formulation of Fenofibric Acid, ABT-335,Co-Administered with Statins: Study Design and Rationale of a Phase III Clinical Programme

Clinical drug investigation, 2008-01, Vol.28 (10), p.625-634

2008

Link zum Volltext

Verfügbarkeit prüfen

Peroxisome Proliferator-Activated Receptors α and γ are Linked with Alcohol Consumption in Mice and Withdrawal and Dependence in Humans

Alcoholism, clinical and experimental research, 2015-01, Vol.39 (1), p.136-145

2015

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of tumor migration and invasion by fenofibrate via suppressing epithelial-mesenchymal transition in breast cancers

Toxicology and applied pharmacology, 2024-02, Vol.483, p.116818-116818, Article 116818

2024

Link zum Volltext

Verfügbarkeit prüfen

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial

Atherosclerosis, 2016-06, Vol.249, p.36-43

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial

Journal of clinical lipidology, 2018-01, Vol.12 (1), p.173-184

2018

Link zum Volltext

Verfügbarkeit prüfen

Targeting DGAT1 inhibits prostate cancer cells growth by inducing autophagy flux blockage via oxidative stress

Oncogene, 2024-01, Vol.43 (2), p.136-150

2024

Link zum Volltext

Verfügbarkeit prüfen

Fibrates for secondary prevention of cardiovascular disease and stroke

Cochrane database of systematic reviews, 2015-10, Vol.2015 (10), p.CD009580

2015

Link zum Volltext

Verfügbarkeit prüfen

A novel therapy for hepatic cholestasis treatment—the combination of rosiglitazone and fenofibrate

European journal of pharmacology, 2023-01, Vol.938, p.175428-175428, Article 175428

2023

Link zum Volltext

Verfügbarkeit prüfen

Delayed treatment with fenofibrate protects against high-fat diet-induced kidney injury in mice: the possible role of AMPK autophagy

American journal of physiology. Renal physiology, 2017-02, Vol.312 (2), p.F323-F334

2017

Link zum Volltext

Verfügbarkeit prüfen

PPAR-α Agonist Fenofibrate Ameliorates Sjögren Syndrome-Like Dacryoadenitis by Modulating Th1/Th17 and Treg Cell Responses in NOD Mice

Investigative ophthalmology & visual science, 2022-06, Vol.63 (6), p.12-12

2022

Link zum Volltext

Verfügbarkeit prüfen

Fenofibrate as a COVID-19 modifying drug: Laboratory success versus real-world reality

Atherosclerosis, 2021-12, Vol.339, p.55-56

2021

Link zum Volltext

Verfügbarkeit prüfen

The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study

Ophthalmology (Rochester, Minn.), 2014-12, Vol.121 (12), p.2443-2451

2014

Link zum Volltext

Verfügbarkeit prüfen

Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events

Cochrane database of systematic reviews, 2018-11, Vol.11 (11), p.CD012502

2018

Link zum Volltext

Verfügbarkeit prüfen

Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes

The New England journal of medicine, 2010-07, Vol.363 (3), p.233-244

2010

Link zum Volltext

Verfügbarkeit prüfen

Regulation of Monocyte Activation by PPARα Through Interaction With the cGAS-STING Pathway

Diabetes (New York, N.Y.), 2023-07, Vol.72 (7), p.958-972

2023

Link zum Volltext

Verfügbarkeit prüfen

Fenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue from diet-induced male obese mice

Molecular and cellular endocrinology, 2015-02, Vol.402, p.86-94

2015

Link zum Volltext

Verfügbarkeit prüfen

Ternary Eutectic Ezetimibe–Simvastatin–Fenofibrate System and the Physical Stability of Its Amorphous Form

Molecular pharmaceutics, 2021-09, Vol.18 (9), p.3588-3600

2021

Link zum Volltext

Verfügbarkeit prüfen

Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

Cochrane database of systematic reviews, 2013-12 (12), p.CD008623-CD008623

2013

Link zum Volltext

Verfügbarkeit prüfen

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

The Lancet (British edition), 2005-11, Vol.366 (9500), p.1849-1861

2005

Link zum Volltext

Verfügbarkeit prüfen

Use of fenofibrate for intrahepatic cholestasis of pregnancy

Journal of hepatology, 2023-08, Vol.79 (2), p.e84-e86

2023

Link zum Volltext

Verfügbarkeit prüfen

Oral Peroxisome Proliferator-Activated Receptor-α Agonist Enhances Corneal Nerve Regeneration in Patients With Type 2 Diabetes

Diabetes (New York, N.Y.), 2023-07, Vol.72 (7), p.932-946

2023

Link zum Volltext

Verfügbarkeit prüfen

New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease

Expert opinion on pharmacotherapy, 2014-03, Vol.15 (4), p.493-503

2014

Link zum Volltext

Verfügbarkeit prüfen

Not enough known about fenofibrate’s kidney effects in people with Type 2 diabetes

Diabetes research and clinical practice, 2024-04, Vol.210, p.111612-111612, Article 111612

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.263

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.146)
Mit Volltextzugriff
(939)

Publikationsform

Sprache

14 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Fenofibrate - Therapeutic Use
(1.128)
Humans
(1.089)
Science & Technology
(962)
Life Sciences & Biomedicine
(945)
Hypolipidemic Agents - Therapeutic Use
(775)
Male
(722)
Female
(574)
Middle Aged
(533)
Fenofibrate
(511)
Adult
(356)
Biological And Medical Sciences
(333)
Medical Sciences
(328)
Aged
(310)
Fenofibrate - Pharmacology
(263)
Animals
(246)
Triglycerides - Blood
(234)
Cardiovascular System & Cardiology
(233)
Pharmacology & Pharmacy
(216)
Treatment Outcome
(205)
Hyperlipidemias - Drug Therapy
(203)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus

Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration

Evaluation of a New Formulation of Fenofibric Acid, ABT-335,Co-Administered with Statins: Study Design and Rationale of a Phase III Clinical Programme

Peroxisome Proliferator-Activated Receptors α and γ are Linked with Alcohol Consumption in Mice and Withdrawal and Dependence in Humans

Inhibition of tumor migration and invasion by fenofibrate via suppressing epithelial-mesenchymal transition in breast cancers

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial

Targeting DGAT1 inhibits prostate cancer cells growth by inducing autophagy flux blockage via oxidative stress

Fibrates for secondary prevention of cardiovascular disease and stroke

A novel therapy for hepatic cholestasis treatment—the combination of rosiglitazone and fenofibrate

Delayed treatment with fenofibrate protects against high-fat diet-induced kidney injury in mice: the possible role of AMPK autophagy

PPAR-α Agonist Fenofibrate Ameliorates Sjögren Syndrome-Like Dacryoadenitis by Modulating Th1/Th17 and Treg Cell Responses in NOD Mice

Fenofibrate as a COVID-19 modifying drug: Laboratory success versus real-world reality

The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study

Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events

Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes

Regulation of Monocyte Activation by PPARα Through Interaction With the cGAS-STING Pathway

Fenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue from diet-induced male obese mice

Ternary Eutectic Ezetimibe–Simvastatin–Fenofibrate System and the Physical Stability of Its Amorphous Form

Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

Use of fenofibrate for intrahepatic cholestasis of pregnancy

Oral Peroxisome Proliferator-Activated Receptor-α Agonist Enhances Corneal Nerve Regeneration in Patients With Type 2 Diabetes

New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease

Not enough known about fenofibrate’s kidney effects in people with Type 2 diabetes

Suchergebnisse filtern